CNSens

CNSens is a biotechnology company headquartered in Lyon, France, that specializes in the development of sensor technologies for monitoring neurochemical activity in the central nervous system. The company was founded in 2018 by a group of neuroscientists and engineers with experience in electrophysiology and microfabrication. Its core mission is to enable high‑resolution, real‑time detection of neurotransmitters and metabolites in both experimental and clinical settings.

CNSens’ product line includes microelectrode arrays and wearable biosensors that can record electrical signals and chemical signals from brain tissue. The technologies are designed to be minimally invasive and are compatible with standard laboratory equipment as well as clinical monitoring systems. The company emphasizes the use of biocompatible materials and advanced signal‑processing algorithms to improve sensitivity and reduce noise.

In addition to its sensor development, CNSens collaborates with academic institutions to study the role of neurochemistry in disorders such as Parkinson’s disease, epilepsy, and depression. The company has secured funding from the European Innovation Council and national research agencies, and it has entered joint‑venture agreements with a few hospitals for clinical trials. CNSens is also involved in developing open‑source software for data analysis, aiming to foster a community of researchers who can share and refine their findings.

References and further information are available on the company’s https://www.cnsens.fr website, which provides details on product specifications, research publications, and partnership opportunities.